Please check your internet connection and try again.
# Lorazepam (Representative Benzodiazepine)
## Overview
Lorazepam is a benzodiazepine with anxiolytic, sedative, hypnotic, amnestic, and anticonvulsant properties. It acts by potentiating the effect of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABA-A receptor.
## Primary Indications
* **Anxiety Disorders:** Management of anxiety symptoms.
* **Insomnia:** Short-term treatment of sleep disturbances.
* **Status Epilepticus:** First-line treatment.
* **Premedication:** Reduction of anxiety and promotion of amnesia before medical procedures.
* **Sedation:** Sedation of intubated patients.
## Adult Dosing
* **Anxiety:** 0.5 mg to 2 mg orally 2 to 3 times daily. Maximum: 10 mg/day.
* **Insomnia:** 2 mg to 4 mg orally at bedtime.
* **Status Epilepticus:** 4 mg IV/IM. Repeat 4 mg if seizure persists after 5 minutes. Maximum: 8 mg.
* **Premedication:** 2 mg to 4 mg orally or IM 2 hours before procedure.
* **Procedural Sedation:** 0.02 mg/kg to 0.06 mg/kg IM/IV, not to exceed 4 mg. Titrate to effect.
* **Intubated Sedation:** 0.02 mg/kg to 0.08 mg/kg IV, may be repeated every 2 hours. Usually 1-4 mg/hour.
*Intramuscular (IM) and intravenous (IV) doses are generally equivalent or slightly higher than oral doses.*
## Pediatric Dosing
Dosing in children is less established and should be individualized based on weight, age, and clinical condition. Consultation with a specialist is recommended.
* **Status Epilepticus:** 0.1 mg/kg IV/IM, not to exceed 4 mg per dose. May repeat once after 5 to 10 minutes.
* **Sedation:** Dosing is highly variable and should be guided by expert consensus or institutional protocol.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution; dose reduction may be necessary.
* **Renal Impairment:** No specific dose adjustment, but use with caution due to potential accumulation.
* **Elderly:** Start at the lower end of the dosing range (e.g., 0.5 mg orally twice daily for anxiety) and titrate slowly. Consider reduced metabolism and increased sensitivity.
## Contraindications
* Known hypersensitivity to benzodiazepines or any component of the formulation.
* Acute narrow-angle glaucoma.
* Severe respiratory insufficiency.
* Severe hepatic insufficiency.
* Myasthenia gravis.
* Sleep apnea.
## Adverse Effects
* **Common:** Drowsiness, dizziness, confusion, ataxia, sedation, fatigue, weakness.
* **Less Common:** Paradoxical excitation, amnesia, blurred vision, nausea, changes in libido, dependence, withdrawal symptoms.
* **Severe:** Respiratory depression, coma, hypotension.
## Key Drug Interactions
* **CNS Depressants (Opioids, Alcohol, Antihistamines, Antipsychotics, Other Sedatives):** Increased risk of profound sedation, respiratory depression, coma, and death. Use concomitant therapy with extreme caution, consider dose reduction of one or both agents.
* **CYP450 Inhibitors/Inducers:** Lorazepam is not significantly metabolized by CYP450 enzymes, so interactions via this pathway are less common compared to other benzodiazepines. However, some sources note potential for interactions with strong inhibitors like fluvoxamine.
* **Theophylline/Aminophylline:** May reduce the sedative effects of lorazepam.
## Monitoring
* **Effectiveness:** Assess reduction in anxiety, improvement in sleep, cessation of seizures, or desired level of sedation.
* **Adverse Effects:** Monitor for excessive sedation, respiratory rate, blood pressure, and cognitive impairment.
* **Dependence/Withdrawal:** Assess for signs of tolerance or withdrawal, particularly with long-term use or abrupt discontinuation.
## Clinical Pearls
* Lorazepam has an intermediate half-life among benzodiazepines.
* It is a preferred benzodiazepine for IM administration due to reliable absorption.
* IV lorazepam should be administered slowly to avoid respiratory depression and hypotension.
* Abrupt discontinuation can lead to withdrawal symptoms including rebound insomnia, anxiety, tremors, and in severe cases, seizures. Tapering is essential.
* Paradoxical reactions (agitation, aggression) can occur, especially in children and the elderly.
***
*This information is intended for clinical professionals. Always refer to the most current prescribing information, institutional protocols, and individual patient factors before making clinical decisions.*
